Hepatic arterial chemotherapy for primary and metastatic liver cancers.
Hepatic arterial chemotherapy represents a means of selectively exposing hepatic tumor to cytotoxic agents. Although 5-fluoro-2'-deoxyuridine has been shown to generate a higher response rate in the treatment of colorectal liver metastases than that achieved by intravenous infusion, responses are largely incomplete and rarely of long duration. This review describes the rationale for the use of the thymidine analogs 5-bromo-2'-deoxyuridine and 5-iodo-2'-deoxyuridine in hepatic arterial infusions and indicates how combination therapy adding radiotherapy, specifically with hepatic arterially administered yttrium-90 microspheres, might generate a new, more efficient and effective therapeutic approach.
Ensminger
W
W
Department of Medicine, University of Michigan Medical School, Ann Arbor.
D001973:Bromodeoxyuridine / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D006499:Hepatic Artery; D006801:Humans; D007065:Idoxuridine / Q000008:administration & dosage*; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000532:radiotherapy; D009362:Neoplasm Metastasis; D015021:Yttrium Radioisotopes / Q000627:therapeutic use
D015021:Yttrium Radioisotopes; D001973:Bromodeoxyuridine; D007065:Idoxuridine